Buch, Englisch, Band 2465, 306 Seiten, Format (B × H): 178 mm x 254 mm, Gewicht: 605 g
Reihe: Methods in Molecular Biology
Methods and Protocols
Buch, Englisch, Band 2465, 306 Seiten, Format (B × H): 178 mm x 254 mm, Gewicht: 605 g
Reihe: Methods in Molecular Biology
ISBN: 978-1-0716-2170-7
Verlag: Springer US
This second edition includes a collection of antigen production and delivery strategies for vaccine development in veterinary species. New and updated chapters guide readers through protocols for antigen production, experimental antigen delivery and the analysis of immune responses upon vaccination. Written in the format of the highly successful Methods in Molecular Biology series, each chapter includes an introduction to the topic, lists necessary materials and reagents, includes tips on troubleshooting and known pitfalls, and step-by-step, readily reproducible protocols.
Authoritative and cutting-edge, Vaccine Technologies for Veterinary Viral Diseases: Methods and Protocols, Second Edition aims to be a useful and practical guide to researches to help further their study in this field.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
- Technische Wissenschaften Maschinenbau | Werkstoffkunde Technische Mechanik | Werkstoffkunde Materialwissenschaft: Biomaterialien, Nanomaterialien, Kohlenstoff
- Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Biotechnologie
- Medizin | Veterinärmedizin Veterinärmedizin Veterinärmedizin
- Naturwissenschaften Chemie Chemie Allgemein
Weitere Infos & Material
An overview of veterinary viral diseases and vaccine technologies.- Production and purification of candidate subunit vaccines by IC-tagging protein encapsulation.- Elastin-like polymers as nanovaccines: protein engineering of self-assembled, epitope-exposing nanoparticles.- Display of heterologous proteins in Bacillus subtilis biofilms for enteric immunization.- Production of influenza H5 vaccine oligomers in plants.- DNA vaccines in pigs: from immunization to antigen identification.- Use of foot-and-mouth disease virus non-coding synthetic RNAs as vaccine adjuvants.- Evaluation of innate lymphoid cells and dendritic cells following viral vector vaccination.- Generation of replication deficient human adenovirus 5 (Ad5) vectored FMD vaccines.- Recombinant modified vaccinia virus Ankara development to express VP2, NS1, and VP7 proteins of Bluetongue virus.- Cloning strategies for the generation of recombinant capripoxvirus through the use of screening and selection markers.- Using Rift Valley fever virus as a vector platform for the expression of ruminant disease antigens.- Generation and characterization of single-cycle infectious canine Influenza A Virus (sciCIV) and its use as vaccine platform.- Reverse genetics for influenza A and B viruses driven by swine polymerase I promoter.- Analysis of the cellular immune responses to vaccines.
